Aspirin Use Tied to Longer Bladder, Breast Cancer Survival
Holli A. Loomans-Kropp, Ph.D., M.P.H., from the National Cancer Institute in Rockville, Maryland, and colleagues investigated the association of aspirin use with the risk for developing new cancers, as well as site-specific cancer-associated survival for bladder, breast, esophageal, gastric, pancreatic, and uterine cancers. The analysis included 139,896 individuals (mean age, 66.4 years) participating in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (1993 to 2001).
The researchers found that aspirin use was not associated with the incidence of any studied cancer type. Aspirin use at least three times/week was associated with increased survival among patients with bladder (hazard ratio, 0.67) and breast (hazard ratio, 0.75) cancers. However, there was no survival benefit with esophageal, gastric, pancreatic, or uterine cancer. A similar association for bladder and breast cancer was seen for any aspirin use (hazard ratios, 0.75 and 0.79, respectively).
"The results presented here add to the accumulating evidence that aspirin may improve survival for some cancers," the authors write.
© 2021 HealthDay. All rights reserved.
Posted: January 2021
Read this next
MONDAY, March 1, 2021 -- In two reports published recently in the American Journal of Roentgenology, radiologists address the clinical features of axillary adenopathy seen on...
TUESDAY, Feb. 16, 2021 -- In a special communication published online Jan. 28 in JAMA Oncology, expert consensus guidelines are presented to enhance clinical practice regarding...
WEDNESDAY, Feb. 10, 2021 -- The risks for breast cancer in women with type 2 diabetes (T2D) may be influenced by long-term metformin use, according to a study published online...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.